EXO-OC algorithm and clinical study update
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Inoviq Ltd has announced an update on the EXO-OC algorithm and its retrospective clinical study, highlighting improvements in diagnostic performance for ovarian cancer detection. The analysis of samples from the expanded clinical study revealed significant variability in sample quality, rendering them unsuitable for evaluating the EXO-OC test. Despite these challenges, the company remains committed to commercializing the EXO-OC test as a Laboratory Developed Test in the US for early detection of ovarian cancer.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Inoviq
- Positive CAR-exosome data in ovarian cancer
- Quarterly Activities Report and Appendix 4C - March 2026
- Appendix 4D and FY26 Half Year Financial Report
- Quarterly Business Update and Appendix 4C - December 2025
- Positive in vivo CAR-EV data in TNBC
Later from Inoviq
- Quarterly Activities Report and Appendix 4C - June 2026
- EXO-OC Study Outcome Investor Webinar Presentation
- EXO-OC Technical Review and Commercialisation Pathway
- INOVIQ Announces Leadership Change
- Quarterly Activities Report and Appendix 4C - September 2026
Follow Inoviq into a list and get an email when it puts out news.
Follow Inoviq